Zacks: Biohaven Pharmaceutical Holding Co Ltd (BHVN) Given Consensus Recommendation of “Strong Buy” by Brokerages

Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) has been given an average broker rating score of 1.30 (Strong Buy) from the five analysts that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company.

Analysts have set a 12-month consensus price objective of $33.40 for the company and are forecasting that the company will post ($0.88) EPS for the current quarter, according to Zacks. Zacks has also given Biohaven Pharmaceutical Holding Co an industry rank of 170 out of 265 based on the ratings given to its competitors.

BHVN has been the subject of several recent research reports. Morgan Stanley initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Wednesday, May 31st. They set an “overweight” rating for the company. William Blair initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They set an “outperform” rating and a $46.00 target price for the company. Barclays PLC initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They set an “overweight” rating and a $30.00 target price for the company. Piper Jaffray Companies initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They set an “overweight” rating and a $21.00 target price for the company. Finally, Needham & Company LLC initiated coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They set a “buy” rating and a $30.00 target price for the company.

In other news, Director Albert Cha purchased 470,000 shares of Biohaven Pharmaceutical Holding Co stock in a transaction that occurred on Tuesday, May 9th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $7,990,000.00. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO James Engelhart purchased 2,500 shares of Biohaven Pharmaceutical Holding Co stock in a transaction that occurred on Tuesday, May 9th. The stock was purchased at an average price of $17.00 per share, with a total value of $42,500.00. Following the transaction, the chief financial officer now owns 3,576 shares in the company, valued at approximately $60,792. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 472,550 shares of company stock valued at $8,033,350.

TRADEMARK VIOLATION WARNING: This article was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.chaffeybreeze.com/2017/06/16/zacks-biohaven-pharmaceutical-holding-co-ltd-bhvn-given-consensus-recommendation-of-strong-buy-by-brokerages.html.

Shares of Biohaven Pharmaceutical Holding Co (NASDAQ BHVN) traded up 10.83% on Friday, hitting $25.58. The company had a trading volume of 606,671 shares. The company has a 50-day moving average of $22.27 and a 200 day moving average of $22.27. Biohaven Pharmaceutical Holding Co has a 12 month low of $17.00 and a 12 month high of $26.28. The stock’s market cap is $334.79 million.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Get a free copy of the Zacks research report on Biohaven Pharmaceutical Holding Co (BHVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply